News

Biogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) 2024 Annual Meeting

Biogen to Participate in the TD Cowen 44th Annual Health Care Conference

Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMP

Biogen Reports Fourth Quarter and Full Year 2023 Results

Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia

Biogen to Realign Resources for Alzheimer's Disease Franchise

BIOGEN TO REPORT FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS FEBRUARY 13, 2024

Update on Marketing Authorization Application for Lecanemab in the European Union

“LEQEMBI®” (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in China